Medexus Pharmaceuticals (TSE:MDP) Upgraded by Raymond James to Strong-Buy Rating

Medexus Pharmaceuticals (TSE:MDP) was upgraded by equities research analysts at Raymond James from an “outperform” rating to a “strong-buy” rating in a research note issued to investors on Wednesday,BayStreet.CA reports. The firm currently has a C$4.00 price objective on the stock. Raymond James’ price objective points to a potential upside of 11.42% from the company’s previous close.

Several other brokerages have also issued reports on MDP. Leede Financial set a C$8.25 price objective on Medexus Pharmaceuticals and gave the company a “speculative buy” rating in a research report on Monday, September 30th. Alliance Global Partners raised shares of Medexus Pharmaceuticals to a “strong-buy” rating in a research note on Monday, December 23rd. Two equities research analysts have rated the stock with a buy rating and four have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Strong Buy” and a consensus price target of C$5.25.

Medexus Pharmaceuticals Stock Up 3.8 %

TSE MDP traded up C$0.13 during trading on Wednesday, reaching C$3.59. 44,051 shares of the stock traded hands, compared to its average volume of 56,940. The stock’s 50-day moving average price is C$2.72 and its 200 day moving average price is C$2.50. The firm has a market cap of C$88.06 million, a price-to-earnings ratio of 71.80 and a beta of 1.96. Medexus Pharmaceuticals has a fifty-two week low of C$1.47 and a fifty-two week high of C$3.59.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.